Antipsychotic treatment for children and adolescents with schizophrenia spectrum disorders: protocol for a network meta-analysis of randomised trials

Bidragets oversatte titel: Antipsychotic treatment for children and adolescents with schizophrenia spectrum disorders: protocol for a network meta-analysis of randomised trials

A. K. Pagsberg, S. Tarp, Dorte Glintborg, A. D. Stenstrom, A. Fink-Jensen, C. U. Correll, Robin Christensen

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Abstrakt

Introduction: Antipsychotic treatment in early-onset schizophrenia (EOS) lacks a rich evidence base, and efforts to rank different drugs concerning their efficacy have not proven any particular drug superior. In contrast to the literature regarding adult-onset schizophrenia (AOS), comparative effectiveness studies in children and adolescents are limited in number and size, and only a few meta-analyses based on conventional methodologies have been conducted. Methods and analyses: We will conduct a network meta-analysis of all randomised controlled trials (RCTs) that evaluate antipsychotic therapies for EOS to determine which compounds are efficacious, and to determine the relative efficacy and safety of these treatments when compared in a network meta-analysis. Unlike a contrast-based (standard) meta-analysis approach, an arm-based network meta-analysis enables statistical inference from combining both direct and indirect comparisons within an empirical Bayes framework. We will acquire eligible studies through a systematic search of MEDLINE, the Cochrane Central Registry of Controlled Trials, Clinicaltrials.gov and Centre for Reviews and Dissemination databases. Eligible studies should randomly allocate children and adolescents presenting with schizophrenia or a related non-affective psychotic condition to an intervention group or to a control group. Two reviewers will - independently and in duplicate - screen titles and abstracts, complete full text reviews to determine eligibility, and subsequently perform data abstraction and assess risk of bias of eligible trials. We will conduct meta-analyses to establish the effect of all reported therapies on patient-relevant efficacy and safety outcomes when possible. Ethics and dissemination: No formal ethical procedures regarding informed consent are required as no primary data collection is undertaken. The review will help facilitate evidence-based management, identify key areas for future research, and provide a framework for conducting large systematic reviews combining direct and indirect comparisons. The study will be disseminated by peer-reviewed publication and conference presentation. Trial registration number: PROSPERO CRD42013006676.

Bidragets oversatte titelAntipsychotic treatment for children and adolescents with schizophrenia spectrum disorders: protocol for a network meta-analysis of randomised trials
OriginalsprogEngelsk
Artikelnummere005708
TidsskriftB M J Open
Vol/bind4
Udgave nummer10
Sider (fra-til)8
Antal sider1
ISSN2044-6055
DOI
StatusUdgivet - 10. okt. 2014

Bibliografisk note

ISI Document Delivery No.: AT2OP Times Cited: 0 Cited Reference Count: 62 Pagsberg, A. K. Tarp, S. Glintborg, D. Stenstrom, A. D. Fink-Jensen, A. Correll, C. U. Christensen, R. RADS ('Radet for Anvendelse af Dyr Sygehusmedicin,' Amgros A/S); RADS ('Radet for Anvendelse af Dyr Sygehusmedicin,' Danske Regioner); Oak Foundation This systematic review and meta-analysis is funded by an RADS ('Radet for Anvendelse af Dyr Sygehusmedicin,' Amgros A/S and Danske Regioner) evidence synthesis grant. The development of this protocol was funded in part by a grant from the Oak Foundation (supporting The Parker Institute). 0 BMJ PUBLISHING GROUP LONDON BMJ OPEN

Fingeraftryk Dyk ned i forskningsemnerne om 'Antipsychotic treatment for children and adolescents with schizophrenia spectrum disorders: protocol for a network meta-analysis of randomised trials'. Sammen danner de et unikt fingeraftryk.

Citationsformater